Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian CAR-T Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentPresbyterian Health PlanPolicy 32.0

    Chimeric Antigen Receptor (CAR) T-cell Therapy

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy 32.0 alerts

    Get alerted when Policy 32.0 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for CAR T-cell therapy, including collection, preparation, and administration-related services and products. Coverage applies to Commercial, Centennial, and Medicare members, subject to the member's specific benefit plan and Presbyterian's use of Optum CAR T-Cell Therapy Clinical Guidelines.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyChimeric Antigen Receptor (CAR) T-cell Therapy
    Policy CodePolicy N/A
    Change TypeAnnual review
    Effective DateAug 7, 2019
    Next Review DateN/A
    Key ActionSubmit CAR-T therapy prior authorization requests through Pres Online.
    SourceLink
    POLICY UPDATE CHANGES

    The 2025 annual review added HCPCS Q2058 and CPT codes 38225, 38226, 38227, and 38228 to the policy.

    CPT codes 0537T, 0538T, 0539T, and 0540T became invalid as of January 1, 2025.

    The policy criteria were replaced with a direction to use Optum CAR T-Cell Therapy Clinical Guidelines.

    RequiredCoverage determination requirement
    3

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Lines of business
    7CAR-T product codes
    2025-08-27Last annual review
    OptumGuideline administrator

    CAR-T Therapy Authorization

    CAR-T Therapy Authorization

    CAR-T therapy requests require prior authorization and are evaluated using Optum CAR T-Cell Therapy Clinical Guidelines.

    ALL of the following

    • Prior authorization is required for CAR-T therapy.
    • Submit the authorization request through Pres Online: https://ds.phs.org/preslogin/index.jsp

      The prior authorization requirement applies to Commercial, Centennial, and Medicare coverage.

    • Requests are evaluated by the Optum transplant team using the Optum CAR T-Cell Therapy Clinical Guidelines.

      PHP continues to use Optum to manage the CAR-T policy; the policy is maintained for informational purposes and does not outline separate drug-specific clinical criteria.

    • For all lines of business, prior authorization is required for the applicable CAR-T and related procedure codes: J3490, J9999, Q2041, Q2042, Q2053, Q2054, Q2055, Q2056, Q2058, 38225, 38226, 38227, and 38228.

      Codes 0537T, 0538T, 0539T, and 0540T were invalid as of 01/01/2025 and are not included in the active prior authorization list.

    Covered and Non-Covered Codes

    CAR-T product codesHCPCSCovered
    Q2041Axicabtagene Ciloleucel (Yescarta), up to 200 Million Autologous Anti-CD19 CAR positive T Cells, including Leukapheresis and dose preparation procedures, per therapeutic dose.
    Q2042Tisagenlecleucel, up to 600 million CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Kymriah).
    Q2053Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Tecartus).
    Q2054Lisocabtagene maraleucel, up to 110 million autologous anti-CD19 CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Breyanzi).
    Q2055Idecabtagene vicleucel, up to 460 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Abecma).
    Q2056Ciltacabtagene autoleucel, up to 100 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Carvykti).
    Q2058Aucatzyl; use Q2058 effective 07/01/2025. For earlier dates, the document specifies C9399 for 11/08/2024-03/31/2025, C9301 for 04/01/2025-06/30/2025, or J3490 for 11/08/2024, with Optum references to J3590 and J9999 through 06/30/2025.
    CAR-T therapy, cell handling, administration, and unclassified drug codesmixedCovered
    38225Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells.
    38226Chimeric antigen receptor T-cell therapy; harvesting or collection/handling of blood-derived T lymphocytes.
    38227Chimeric antigen receptor T-cell therapy; preparation of blood-derived T lymphocytes for transportation.
    38228Chimeric antigen receptor T-cell therapy; receipt and preparation of CAR-T cells for administration and CAR-T cell administration.
    J3490Unclassified drugs or biologicals; autologous CAR-T product billing may apply as specified in the policy.
    J3590Unclassified drugs or biologicals.
    J9999Unclassified drugs or biologicals.
    Temporary or alternate Aucatzyl billing codesHCPCS
    C9399Temporary code specified for Q2058/Aucatzyl for dates of service 11/08/2024-03/31/2025.
    C9301Temporary code specified for Q2058/Aucatzyl for dates of service 04/01/2025-06/30/2025.
    Historical, deleted, removed, or invalid codesmixedNot Covered
    0537THistorical CAR-T code; invalid as of 01/01/2025.
    0538THistorical CAR-T code; invalid as of 01/01/2025.
    0539THistorical CAR-T code; invalid as of 01/01/2025.
    0540THistorical CAR-T code; invalid as of 01/01/2025.
    05340TCode written in the publication history as 05340T.
    C9073Deleted 04/01/2021; report Q2053 instead.
    C9076Removed from the policy in the 2022 annual review.
    Q2043Removed from the policy due to error.
    Q2049Removed from the policy due to error.

    Authorization and Documentation Requirements

    Prior Authorization

    Submit Prior Authorization Through Pres Online

    Submit CAR-T therapy prior authorization requests through Pres Online before services are provided.

    • Pres Online: https://ds.phs.org/preslogin/index.jsp
    • Applies to Commercial, Centennial, and Medicare coverage.
    Billing Rule

    New CAR-T Codes Require Policy Review

    The 2025 policy update added new CAR-T-related codes that require policy review and should be evaluated under the applicable coverage and authorization requirements.

    • HCPCS Q2058
    • CPT 38225, 38226, 38227, and 38228

    CAR-T Therapy Background

    CAR T-cells and genetically engineered TCR T-cells are manufactured by collecting lymphocytes from the patient and modifying them ex vivo through gene-transfer techniques. Viral vectors introduce receptors designed to recognize the patient’s tumor antigens. The engineered cells are then infused back into the patient to direct a targeted immune response against cancerous tissue. CAR T-cell therapy is most commonly used for hematologic malignancies, frequently targeting the B-cell antigen CD19.

    Key CAR-T Terms

    CAR T-cell therapy
    DefinitionGenetically engineered T cells manufactured from collected patient lymphocytes, modified ex vivo to express tumor-antigen-specific receptors, and reinfused to direct an immune response against malignant tissue.
    Chimeric antigen receptor
    StructureA hybrid receptor containing an extracellular single-chain antibody fragment, a transmembrane domain, and at least one intracellular signaling domain.
    CD19
    DefinitionA tumor-associated B-cell antigen commonly targeted by CAR T-cell therapy.

    Required Biomarkers

    CD19
    BiomarkerCD19 is the target antigen commonly associated with anti-CD19 CAR T-cell products, including axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and lisocabtagene maraleucel.
    BCMA
    BiomarkerBCMA is the target antigen for idecabtagene vicleucel and ciltacabtagene autoleucel products.

    Covered CAR-T Products and Indications

    ProductCovered indication
    Axicabtagene ciloleucel (Yescarta), an anti-CD19 CAR T-cell product
    B-cell malignancies and other indications addressed by the applicable product labeling and Optum CAR T-Cell Therapy Clinical Guidelines
    ProductCovered indication
    Tisagenlecleucel (Kymriah), an anti-CD19 CAR T-cell product
    CD19-positive B-cell malignancies addressed by the applicable product labeling and Optum CAR T-Cell Therapy Clinical Guidelines
    ProductCovered indication
    Brexucabtagene autoleucel (Tecartus)
    Mantle cell lymphoma
    ProductCovered indication
    Lisocabtagene maraleucel (Breyanzi)
    Large B-cell lymphoma and diffuse large B-cell lymphoma
    ProductCovered indication
    Idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti)
    Multiple myeloma
    Policy Summary
    PayerPresbyterian Health Plan
    PolicyChimeric Antigen Receptor (CAR) T-cell Therapy
    Policy CodePolicy N/A
    Change TypeAnnual review
    Effective DateAug 7, 2019
    Next Review DateN/A
    Key ActionSubmit CAR-T therapy prior authorization requests through Pres Online.
    SourceLink
    On This Page
    CAR-T Therapy AuthorizationCovered and Non-Covered CodesAuthorization and Documentation RequirementsCAR-T Therapy BackgroundKey CAR-T TermsRequired BiomarkersCovered CAR-T Products and Indications
    Documentation Required

    Maintain Coverage-Supporting Documentation

    Providers must maintain or have access to appropriate guideline and source-material documentation to support coverage when requested.

    • Presbyterian uses Optum CAR-T Cell Therapy Clinical Guidelines.
    • See the policy References section for source materials used to develop the policy.
    Documentation Required

    Submit Additional Medical Necessity Information

    If the member does not meet the applicable guideline criteria, providers may submit additional information supporting medical necessity for consideration by the medical director.

    • Supplemental information may be used by the medical director when reviewing the case.
    Note

    Verify Member-Specific Benefits

    Coverage is determined by the member's specific benefit plan and Schedule of Benefits; this policy may not apply to every plan and benefits may be broader or more limited than described here.

    • Verify member-specific benefits before proceeding with treatment or authorization.
    Denial Risk

    Prior Authorization Required

    Prior authorization is required for CAR-T therapy. Failure to obtain required authorization before treatment may result in noncoverage or denial.

    • Confirm authorization requirements and approval before services are rendered.
    Documentation Required

    Support Coverage With Guideline Documentation

    When Presbyterian applies an external guideline to determine coverage, providers are expected to maintain or have access to the relevant documentation and provide it when requested to support the coverage determination.

    • Applicable guideline documentation includes the Optum CAR-T Cell Therapy Clinical Guidelines and other source materials identified in the policy.